Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04270383
Other study ID # BCH Lung 012
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 15, 2020
Est. completion date December 31, 2020

Study information

Verified date February 2020
Source Beijing Children's Hospital
Contact Baoping Xu, MD,PhD
Phone 861059616308
Email xubaopingbch@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study is designed to clarify the clinical characteristics, risk factors and long-term prognosis of children with 2019-nCoV infection in China.


Description:

As of February 10th, 2020, more than 40,000 human have been confirmed infected with a novel coronavirus (2019-nCoV) in China, with at least 800 reported deaths. Additional cases have been confirmed in multiple countries, and some are reported in children. Patients with confirmed 2019-nCoV infection have reported respiratory illness with fever, cough, et al. Some are asymptomatic carriers. However, there are relatively few diagnosed cases of children, and the long-term prognosis is unknown. Therefore, a multicenter observational study is needed to better understand the clinical characteristics of 2019-nCoV infection in children.

This observational study will last from February to December 2020. The patients enrolled were diagnosed with 2019-nCoV infection or 2019-nCoV pneumonia by Beijing Children's Hospital and other members of Chinese National Clinical Research Center for Respiratory Diseases in 2019-2020. At the same time, children hospitalized with pneumonia other than 2019-nCoV pneumonia during the same period are classified as the control group by 3~5:1 matching for age and sex to the 2019-nCoV group. After guardians signing the informed consent forms, all the participants' clinical data, laboratory examination results, image data and also the follow-up information after six months of their treatment will be collected.

The trial will be completed in 10 months, with subjects recruited from the hospitals that in partnership with clinical research collaboration of National Clinical Research Center for Respiratory Diseases.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility 1. For the 2019-nCoV infection group

Inclusion Criteria:

Diagnosed with 2019-nCoV infection (with direct laboratory evidence).

1. Respiratory or blood samples tested positive for novel coronavirus nucleic acid with RT-PCR.

2. Gene sequencing of respiratory or blood samples show highly homologous with known novel coronaviruses.

Exclusion Criteria:

Subjects will be excluded if the children or their parents disagree to conduct this study.

2. For the control group

Inclusion Criteria:

1. Diagnosed with pneumonia, and excepted of novel coronavirus infection.

2. The hospitalization time is the same as that of novel coronavirus pneumonia.

Exclusion Criteria:

Subject will be excluded if she or he has one of the following:

1. First diagnosis is not pneumonia.

2. Any one of the novel coronavirus laboratory test results show positive.

3. Children or their parents disagree to conduct this study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Children's Hospital, Beijing

Sponsors (23)

Lead Sponsor Collaborator
Beijing Children's Hospital Capital Institute of Pediatrics, China, Changchun Children's Hospital, Children's Hospital of Chongqing Medical University, Children's Hospital of Hebei Province, Children’s Hospital of Nanjing Medical University, China-Japan Friendship Hospital, First Affiliated Hospital of Guangxi Medical University, Guangzhou Women and Children's Medical Center, Hainan People's Hospital, Jiangxi Province Children's Hospital, Kunming Children's Hospital, Second Affiliated Hospital of Wenzhou Medical University, Shanxi Provincial Maternity and Children's Hospital, Shengjing Hospital, Shenzhen Children's Hospital, The Affiliated Hospital Of Guizhou Medical University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Xiamen University, Tianjin Children's Hospital, Tianjin Medical University Second Hospital, Wuhan Women and Children's Medical Center, Xian Children's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The cure rate of 2019-nCoV. Percentage 6 months
Primary The improvement rate of 2019-nCoV. Percentage 6 months
Primary The incidence of long-term adverse outcomes. 6 months
Secondary Duration of fever Days 2 weeks
Secondary Duration of respiratory symptoms Days 2 weeks
Secondary Duration of hospitalization Days 2 weeks
Secondary Number of participant(s) need intensive care 2 weeks
Secondary Number of participant(s) with acute respiratory distress syndrome 2 weeks
Secondary Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al. 2 weeks
Secondary Number of participant(s) who died during the trial 10 months
See also
  Status Clinical Trial Phase
Suspended NCT04334967 - Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Phase 4
Not yet recruiting NCT04264858 - Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients N/A
Withdrawn NCT04272710 - Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Completed NCT04260594 - Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus Phase 4
Active, not recruiting NCT04273763 - Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) N/A
Terminated NCT04261907 - Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection N/A
Not yet recruiting NCT04261426 - The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia Phase 2/Phase 3
Recruiting NCT04255017 - A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia Phase 4
Recruiting NCT04254874 - A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia Phase 4
Not yet recruiting NCT04356508 - COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 Phase 2
Terminated NCT04321928 - Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary N/A